Other Products to Explore
Just out of the assay pipeline, Siemens Healthineers has achieved 510(k) clearance from the FDA for its N Latex FLC kappa and N Latex FLC lambda assays for monitoring multiple myeloma. The assays are confirmed to be highly precise and sensitive for free light chain quantification compared to the immunofixation method currently regarded as the reference method for detection of monoclonal immunoglobulins and its components.
Ad Statistics
Times Displayed: 109208
Times Visited: 6638 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Siemens Healthineers will also unveil a new product for point-of-care testing. "Point-of-care testing enables clinicians to deliver the right test in the right setting for their patients at the right time," said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers. "Siemens Healthineers will be unveiling its newest technology for point-of-care testing—the RAPIDPoint 500e Blood Gas System." The RAPIDPoint® 500e Blood Gas System,3 will be revealed on Tuesday, August 6 for product demonstrations.
Clinicians who use Siemens Healthineers products will speak about industry hot topics such as high-sensitivity cardiac troponin I, free light chain testing in the diagnosis and monitoring of multiple myeloma, and effective chronic disease management utilizing point-of-care testing. To learn more about these presentations, please visit https://www.siemens-healthineers.com/aacc.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
Back to HCB News
